Want to see JP:2931 full AI Analyst Report?
2931 Stock Chart & Stats
¥407.00
-¥7.00(-1.67%)
At close: 4:00 PM EST
¥407.00
-¥7.00(-1.67%)
Day’s Range― - ―
52-Week Range¥318.00 - ¥513.00
Previous CloseN/A
Volume629.20K
Average Volume (3M)958.05K
Market Cap
¥47.57B
Enterprise Value¥60.12K
Total Cash (Recent Filing)¥18.87B
Total Debt (Recent Filing)¥25.45B
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding139,521,760
10 Day Avg. Volume1,429,850
30 Day Avg. Volume958,053
Financial Highlights & Ratios
PEG Ratio-3.10
Price to Book (P/B)1.76
Price to Sales (P/S)1.08
P/FCF Ratio10.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.8
Revenue Forecast (FY)¥51.90B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthMeaningful multi-year revenue growth from ¥13.3B to ¥50.4B demonstrates successful commercialization and scaling of Euglena-based products. Durable top-line expansion improves fixed-cost absorption, supports broader distribution and brand recognition, and underpins long-term operating leverage as the business scales.
Cash GenerationMaterial strengthening of operating and free cash flow in 2024–2025 shows improved cash discipline and conversion. Sustained FCF provides internal funding for R&D, capex and working capital, reduces dependence on external financing, and supports reinvestment into products and supply capability over the medium term.
High Gross Margins & Operating RecoveryConsistently high gross margins and a shift to positive operating profit indicate durable unit economics and improving core profitability. Strong product-level margins provide pricing flexibility and resilience to input cost swings, making continued operating profit growth more attainable as revenue scales further.
Bears Say
Net Losses & Negative ROEPersistent net losses and negative ROE mean shareholder capital has yet to generate positive returns. Until net profitability is sustained, the company may need external capital, which can dilute shareholders or constrain strategic choices and limit the long-term improvement in equity returns.
Higher Absolute Debt LevelsEven with improved debt ratios, rising absolute debt increases interest and refinancing exposure and reduces financial flexibility. Higher nominal debt can limit the ability to pursue larger capex or M&A and makes the company more sensitive to cash-flow variability or adverse rate moves over the medium term.
Modest Cash Conversion & VolatilityDespite recent FCF gains, cash conversion relative to revenue remains modest and historical OCF volatility (including negative periods) indicates earnings do not fully translate into predictable cash. This undermines planning, capital allocation and resilience to shocks without resorting to external funding.
euglena Co., Ltd. News
2931 FAQ
What was euglena Co., Ltd.’s price range in the past 12 months?
euglena Co., Ltd. lowest stock price was ¥318.00 and its highest was ¥513.00 in the past 12 months.
What is euglena Co., Ltd.’s market cap?
euglena Co., Ltd.’s market cap is ¥47.57B.
When is euglena Co., Ltd.’s upcoming earnings report date?
euglena Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 4 days.
How were euglena Co., Ltd.’s earnings last quarter?
euglena Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥0.23 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is euglena Co., Ltd. overvalued?
According to Wall Street analysts euglena Co., Ltd.’s price is currently Overvalued.
Does euglena Co., Ltd. pay dividends?
euglena Co., Ltd. pays a N/A dividend of ¥2 which represents an annual dividend yield of N/A. See more information on euglena Co., Ltd. dividends here
What is euglena Co., Ltd.’s EPS estimate?
euglena Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does euglena Co., Ltd. have?
euglena Co., Ltd. has 139,521,760 shares outstanding.
What happened to euglena Co., Ltd.’s price movement after its last earnings report?
euglena Co., Ltd. reported an EPS of -¥0.23 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.998%.
Which hedge fund is a major shareholder of euglena Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2931
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
euglena Co., Ltd.
Euglena Co., Ltd. is a Japanese enterprise specializing in the research, development, cultivation, and marketing of microalgae. Its operations are structured around two primary divisions: Healthcare Business and Energy/Environment Business. The company manufactures and sells a variety of euglena-derived food items and cosmetics. Additionally, it offers a broad portfolio of consumer goods, such as health foods, beverages, confectionery, and sports nutrition products. Furthermore, Euglena is engaged in pioneering biofuel and environmental technologies leveraging microalgae, and it makes strategic investments in the biotechnology sector. Its merchandise is distributed through numerous retail channels, including convenience stores, pharmacies, grocery stores, beauty parlors, and various specialty retailers. The company was established in Tokyo, Japan, in 2005.
Technical Analysis
Kao
―
Kobayashi Pharmaceutical Co
―
Kose
―
Rohto Pharmaceutical Co
―
Shiseido Company,Limited
―